• BCLC
• HCC
• biomarker
• cutoff
• hepatocellular carcinoma
• platelets
• survival

• C3G (RapGEF1)
• immune response
• liver cancer
• liver fibrosis
• platelet

• Animals
• Blood Platelets/metabolism
• Blood Platelets/immunology
• Mice, Knockout
• Liver Cirrhosis/pathology
• Liver Cirrhosis/immunology
• Liver Cirrhosis/metabolism
• Liver Cirrhosis/chemically induced
• Liver Cirrhosis/genetics
• Mice, Inbred C57BL
• Carbon Tetrachloride
• Liver Neoplasms/immunology
• Liver Neoplasms/pathology
• Liver Neoplasms/metabolism
• Liver Neoplasms/genetics
• Mice
• Macrophages/immunology
• Macrophages/metabolism
• Liver/pathology
• Liver/immunology
• Liver/metabolism
• Male
• Platelet Activation

• PID2019-104143RB-C21 Ministerio de Ciencia, Tecnología e Innovación
• PID2019-104143RB-C22 Ministerio de Ciencia, Tecnología e Innovación
• PID2022-136959OB-I00 Ministerio de Ciencia, Tecnología e Innovación
• PID2022-137717OB-C21 Ministerio de Ciencia, Tecnología e Innovación
• PID2022-137717OB-C22 Ministerio de Ciencia, Tecnología e Innovación
• Ministerio de Ciencia, Tecnología e Innovación

• cancer patient
• oncologic benefit
• partial splenic embolization
• systemic chemotherapy
• transarterial chemoembolization

• Cancer
• Prognosis
• Survival outcomes
• Thrombocytosis
• Umbrella review

• Humans
• Meta-Analysis as Topic
• Neoplasms/blood
• Neoplasms/complications
• Neoplasms/mortality
• Neoplasms/therapy
• Platelet Count
• Prognosis
• Survival Analysis
• Thrombocytosis/blood
• Thrombocytosis/complications
• Thrombocytosis/epidemiology

• cancer‐specific survival
• intrahepatic cholangiocarcinoma
• overall survival
• platelet count
• prognosis
• thrombocytosis

• Humans
• Cholangiocarcinoma/surgery
• Cholangiocarcinoma/blood
• Cholangiocarcinoma/pathology
• Cholangiocarcinoma/mortality
• Female
• Male
• Platelet Count
• Bile Duct Neoplasms/surgery
• Bile Duct Neoplasms/pathology
• Bile Duct Neoplasms/blood
• Bile Duct Neoplasms/mortality
• Middle Aged
• Hepatectomy/mortality
• Aged
• Prognosis
• Survival Rate
• Follow-Up Studies
• Retrospective Studies

• HCC
• biomarkers
• size
• survival

• R01 CA082723 NCI NIH HHS

• circulating tumor DNA
• circulating tumor cells
• exosomes
• hepatocellular carcinoma
• liquid biopsy
• liver transplantation

• 2022BCA015 Key Research and Development Plan of Hubei Province
• WJ2021C001 the Health Commission of Hubei Province

• Extrahepatic metastasis
• Hepatocellular carcinoma
• Platelet count
• Vascular invasion

• C3G/RAPGEF1
• EGFR
• HGF
• MET
• TGF-β
• liver cancer
• platelets
• tumor microenvironment

• Humans
• Liver Neoplasms/metabolism
• Carcinoma, Hepatocellular/metabolism
• Liver/metabolism
• Hepatocytes/metabolism
• Liver Cirrhosis/metabolism
• Fibrosis
• Transforming Growth Factor beta/metabolism
• Inflammation/metabolism
• Tumor Microenvironment

• 10.13039/501100011033 Agencia Estatal de Investigación
• PID2019-104143RB-C22 Agencia Estatal de Investigación
• PID2019-104991RB-I00 Agencia Estatal de Investigación
• PID2020-117650RA-I00 Agencia Estatal de Investigación
• PID2021-124830OB-I00 Agencia Estatal de Investigación

• Clinical features
• Early recurrence
• Hepatocellular carcinoma
• Imaging features
• Machine learning
• Risk prediction models

• Humans
• Carcinoma, Hepatocellular/pathology
• Liver Neoplasms/pathology
• Retrospective Studies
• Risk Factors
• Machine Learning

• aspartate aminotransferase to platelet ratio
• disease-free survival
• hepatocellular carcinoma
• overall survival

• BG20228542 Major Project of Scientific Research Foundation, Zhongshan city people's hospital
• 81871323 and 81801665 National Natural Science Foundation of China
• 2018B030311024 National Natural Science Foundation of Guangdong Province
• 21620447 the Scientific Research Cultivation and Innovation Foundation of Jinan University
• National Natural Science Foundation of China

• ALBI
• EZ-ALBI
• MELD
• PAL
• PALBI
• hepatocellular carcinoma

• T32 DK007745 NIDDK NIH HHS

• Cross-talk
• Hepatocellular carcinoma
• Immunity
• PRKCD
• Platelet
• Prognosis

• elastography
• flow cytometry
• liver cirrhosis
• monitoring
• platelet aggregation
• platelet count
• risk assessment
• thrombopoietin

• Blood Platelets/pathology
• Fibrosis
• Humans
• Kinetics
• Liver Cirrhosis/pathology
• Liver Diseases/pathology
• Thrombopoietin

• MOST 104-2314-B-039-014- Ministry of Science and Technology
• MOST 107-2314-B-039-007- Ministry of Science and Technology
• MOST 108-2314-B-039-051- Ministry of Science and Technology
• DMR-111-029 China Medical University Hospital

• Carcinoma, Hepatocellular/complications
• Carcinoma, Hepatocellular/diagnosis
• Carcinoma, Hepatocellular/pathology
• End Stage Liver Disease/complications
• Humans
• Hypercalcemia/complications
• Hypercholesterolemia/complications
• Hypoglycemia/etiology
• Liver Neoplasms/pathology
• Paraneoplastic Syndromes/diagnosis
• Paraneoplastic Syndromes/etiology
• Polycythemia/complications
• Prognosis
• Retrospective Studies
• Severity of Illness Index
• Thrombocytosis/complications
• alpha-Fetoproteins/analysis

• HCC
• PVT
• cirrhosis
• coagulation
• fibrinolysis
• platelets
• thrombosis

• Erythrocytosis
• hepatocellular carcinoma
• hypercalcemia
• hypercholesterolemia
• hypoglycemia
• paraneoplastic syndrome
• thrombocytosis

• Carcinoma, Hepatocellular/diagnosis
• Carcinoma, Hepatocellular/therapy
• Humans
• Liver Neoplasms/diagnosis
• Liver Neoplasms/therapy
• Paraneoplastic Syndromes/diagnosis
• Paraneoplastic Syndromes/etiology
• Paraneoplastic Syndromes/therapy
• Quality of Life
• Survival Rate

Myelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet–large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear.

This study aims to explore the impact of the P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment.

In the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used the bioinformatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCR^low and P-LCR^high groups, and their characteristics were compared between the two groups.

Results show that the P-LCR^low was associated with worse overall survival (OS) than the P-LCR^high patients (median OS, 18.53 months versus 25.77 months, p=0.0057), but there were no statistical differences in progression-free survival (PFS) between the two groups (p=0.2001). The results of univariate and multivariate Cox proportional hazard analyses adjusted for gender, bone marrow blast level, platelet count, and International Prognostic Scoring System scores showed that the P-LCR was useful in the evaluation of PFS [hazard ratio (HR) 0.212, 95%CI 0.064–0.702, p=0.011] and OS of MDS (HR 0.464, 95%CI 0.284–0.757, p=0.002).

This study is the first report showing that the P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS.

• Huai’an Science and Technology Bureau
• Jiangsu Commission of Health

• AF, atrial fibrillation
• CAD, coronary artery disease
• CHIP, clonal hematopoiesis of indeterminate potential
• CI, confidence interval
• CLEC-2, C-type lectin-like receptor 2
• HR, hazard ratio
• IL, interleukin
• MI, myocardial infarction
• PCI, percutaneous coronary intervention
• ROS, reactive oxygen species
• TKI, tyrosine kinase inhibitor
• VTE, venous thromboembolism
• arrhythmia
• risk factor
• thrombosis

Patients with small hepatocellular carcinoma (HCC) (3 cm) still have a poor prognosis. The purpose of this study was to develop a radiomics nomogram to preoperatively predict early recurrence (ER) (2 years) of small HCC.

The study population included 111 patients with small HCC who underwent surgical resection (SR) or radiofrequency ablation (RFA) between September 2015 and September 2018 and were followed for at least 2 years. Radiomic features were extracted from the entire tumor by using the MaZda software. The least absolute shrinkage and selection operator (LASS0) method was applied for feature selection, and radiomics signature construction. A rad-score was then calculated. Multivariable logistic regression analysis was used to establish a prediction model including independent clinical risk factors, radiologic features and rad-score, which was ultimately presented as a radiomics nomogram. The predictive ability of the nomogram was evaluated using the area under the receiver operating characteristic (ROC) curve and internal validation was performed via bootstrap resampling and 5-fold cross-validation method.

A total of 53 (53/111, 47.7%) patients had confirmed ER according to the final clinical outcomes. In univariate logistic regression analysis, cirrhosis and hepatitis B infection (P=0.015 and 0.083, respectively), hepatobiliary phase hypointensity (P=0.089), Child-Pugh score (P=0.083), the preoperative platelet count (P=0.003), and rad-score (P<0.001) were correlated with ER. However, after multivariate logistic regression analysis, only the preoperative platelet count and rad-score were included as predictors in the final model. The area under ROC curve (AUC) of the radiomics nomogram to predict ER of small HCC was 0.981 (95% CI: 0.957, 1.00), while the AUC verified by bootstrap is 0.980 (95% CI: 0.962, 1.00), indicating the goodness-of-fit of the final model.

The radiomics nomogram containing the clinical risk factors and rad-score can be used as a quantitative tool to preoperatively predict individual probability of ER of small HCC.

• hepatocellular carcinoma
• magnetic resonance imaging
• nomogram
• radiomics
• recurrence

• Von Willebrand factor
• aggregation
• cancers
• cirrhosis
• hepatocellular carcinoma
• platelets

• UL1 TR001863 NCATS NIH HHS

Platelet–albumin–bilirubin (PALBI) has been demonstrated to be superior to conventional Child–Pugh (C-P) grade in evaluating liver function and prognosis of HCC patients. However, both thrombocytosis and thrombocytopenia are unfavorable for HCC survival. The aim of this study was to preliminarily investigate the prognostic value of PALBI in HCC patients with thrombocytopenia and excluding thrombocytopenia.

In this retrospective cohort study, we reviewed 465 cases of HCC patients who underwent radical surgery. PALBI grade was calculated based on preoperative serological examinations. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS), which were assessed by Kaplan–Meier method and Cox regression. The prognostic performances of PALBI and other models were estimated by using the concordance index (C-index).

During a median follow-up time of 28 months, 31.6% (147/465) of patients died and 33.5% (156/465) experienced recurrence. Multivariate analyses revealed that both thrombocytosis and thrombocytopenia were independently associated with poor OS and RFS compared with normal platelet count (PLT) in HCC patients. Stratified analysis further revealed that PALBI was a significant predictor for HCC survival in patients excluding thrombocytopenia but not in patients with thrombocytopenia. In particular, in HCC patients excluding thrombocytopenia, the combination of tumor size with PALBI (C-index = 0.730, 95% CI: 0.674–0.786) may be superior to the classical Barcelona Clinic Liver Cancer (BCLC) and Cancer of Liver Italian Program (CLIP) staging systems in predicting survival.

In conclusion, PALBI grade, in particular the combination with tumor size, is an effective model for discriminating survival in HCC patients excluding thrombocytopenia but not in thrombocytopenic HCC patients.

• hepatocellular carcinoma
• platelet count
• platelet–albumin–bilirubin
• survival

Platelet count (PLT) has been proved as an essential biomarker for the survival of hepatocellular carcinoma (HCC). However, the prognostic value of PLT change (ΔPLT) is still uncertain. The aim of this study was to explore the relationship between ΔPLT and HCC survival after transarterial chemoembolization (TACE) treatment.

Cox proportional hazard regression models were used to calculate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for HCC. The non-linear relationship between ΔPLT and OS was estimated through a restricted cubic spline regression analysis, and a two-piece-wise Cox proportional hazard model was further performed to calculate the threshold effect.

A total of 597 HCC patients treated with TACE were selected for the secondary analysis. Compared with the ΔPLT within ±20 (×10⁹/L), ΔPLT≥20 (×10⁹/L) was significantly associated with an 64% increase in risk of death (HR, 1.64; 95% CI: 1.21 to 2.22) after adjustment for confounding variables, but the association was not significant in the group of ΔPLT≤-20 (HR, 1.23; 95% CI: 0.92 to 1.63). We also found a U-shape relationship between ΔPLT and HCC survival at the turning point of ΔPLT as 0 (20×10⁹/L). The HR for the death was 1.12 (95% CI: 1.06, 1.18) with ΔPLT≥0 (20×10⁹/L) while 0.95 (95% CI: 0.92, 0.98) with ΔPLT<0 (20×10⁹/L). After potential confounding factors were adjusted, the non-linear relationship between ΔPLT and OS was still significant (P=0.013). Besides, ΔPLT≥20 (×10⁹/L) was associated with new lesions (OR, 2.74; 95% CI: 1.38 to 5.45).

Elevated PLT was associated with poor overall survival of HCC patients after TACE treatment.

• hepatocellular carcinoma
• platelet count
• prognosis
• real-world study
• transarterial chemoembolization

• growth factor
• hepatocellular carcinoma
• platelet
• portal hypertension
• prognostic predictor